Pam2csk4
Also known as: Dipalmitoyl-CSK4, Pam2CSK4, S-[2,3-Bis(palmitoyloxy)propyl]cysteine-serine-(lysine)4, TLR2/6 agonist lipopeptide
Source Pam2csk4 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pam2CSK4 is a synthetic diacylated lipopeptide used as a potent TLR2/6 agonist in immunology research and as an experimental vaccine adjuvant. It is not approved for clinical use.
Mechanism of Action
Diacylated lipopeptide that binds and activates Toll‑like receptor 2/6 heterodimer, triggering NF‑κB signaling and pro‑inflammatory cytokine production
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Mucosal immunity inductionImmunologyModerate
- TLR2/TLR6 pathway research toolBasic ResearchHigh
- Anti-infective prophylaxis (research)Infectious DiseaseLow
- Innate immune activationImmunostimulationHigh
- Innate immunity researchResearch ToolHigh
- TLR2 activationImmunostimulationHigh
Contraindications
- Systemic administration in inflammatory conditionsClinicalHigh
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- Sepsis-like syndrome (high dose)Systemic ToxicityRare
- Pro-inflammatory cytokine release (TNF-α, IL-6, IL-12)Systemic Immune ReactionCommon
- Fever / pyrogenicitySystemic Immune ReactionUncommon
- Local inflammationLocalCommonInflammatory response at or near the administration site
- Local inflammation at injection siteLocal ReactionCommon
- Systemic cytokine releaseSystemicUncommon
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, tacrolimus)Moderate
- Other TLR agonistsModerate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- ElderlyAgeRelative
- Immunocompromised animals/modelsPreclinicalRelative
- ChildrenPediatricRelative
- Human subjectsRegulatory/SafetyAbsolute
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesUnapprovedInvestigational reagent only
- United KingdomUnapprovedResearch grade only
No regulatory approval; classified as a research reagent. Not intended for human administration outside of controlled clinical trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Pam2csk4?
Pam2CSK4 is a synthetic diacylated lipopeptide used as a potent TLR2/6 agonist in immunology research and as an experimental vaccine adjuvant. It is not approved for clinical use.
What is Pam2csk4 used for?
Pam2csk4 is educationally associated with: Vaccine adjuvant, Mucosal immunity induction, TLR2/TLR6 pathway research tool, Anti-infective prophylaxis (research), Innate immune activation, Innate immunity research, TLR2 activation. Educational only — not medical advice.
How is Pam2csk4 administered?
Recorded routes of administration: In Vitro, Intradermal, Intramuscular, Intranasal, Intraperitoneal, Intravenous, Subcutaneous, Topical.
What are the potential side effects of Pam2csk4?
Reported adverse effects include: Sepsis-like syndrome (high dose), Pro-inflammatory cytokine release (TNF-α, IL-6, IL-12), Fever / pyrogenicity, Local inflammation, Local inflammation at injection site, Systemic cytokine release. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pam2csk4?
Recorded contraindications: Systemic administration in inflammatory conditions, Autoimmune disease, Pregnancy, Human therapeutic use. Consult a qualified clinician before use.